T Lymphocyte News and Research

RSS
Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

New treatment option available for CLL patients in Manitoba and Saskatchewan

New treatment option available for CLL patients in Manitoba and Saskatchewan

University of Oslo researchers find the cause of coeliac disease

University of Oslo researchers find the cause of coeliac disease

Damon Runyon creates new award to increase number of physician-scientists

Damon Runyon creates new award to increase number of physician-scientists

Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Modifying small white blood cells may help treat immune disorders

Modifying small white blood cells may help treat immune disorders

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Massey researchers aim to develop models that can predict complications from stem cell transplantation

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

FDA clears AQUIOS CL Flow Cytometer for routine immunophenotyping applications in US clinical labs

FDA clears AQUIOS CL Flow Cytometer for routine immunophenotyping applications in US clinical labs

Pembrolizumab effective, well-tolerated in advanced melanoma patients

Pembrolizumab effective, well-tolerated in advanced melanoma patients

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Scientists discover protein that boosts immunity to viruses and cancer

Scientists discover protein that boosts immunity to viruses and cancer

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.